Budget Impact Analysis of 13-Valent Pneumococcal Vaccine in Adult Population with Comorbidities or Immunocompromised from the Public Payer Perspective In Brazil

Abstract

Objectives: The surgical site infection (SSI) is the most often acquired hospital infection in Spain, about 19.4% of all nosocomial infections. The prevalence of this adverse event is 8.01%, generating high economic impact on hospital costs and undermining the quality of care. The risk of SSI has increased in recent years and infections have become more resistant to treatments. About 50% of SSIs are preventable, their costs are avoidable, and health technology can help avoiding them. The aim of this study is to analyze the economic impact that could represent the use of anti-bacterial sutures compared with conventional ones in Spanish hospitals. MethOds: An interactive Excel model was developed using data obtained through a published literature review. The rate of reduction of SSI with antibacterial suture is 30%. The incremental cost per patient with SSI is between € 9,657 and € 10,112.63. Two scenarios were designed: 100% of surgeries with normal sutures and 100% of surgeries with anti-bacterial sutures. A sensitivity analysis for the variables of greatest uncertainty was performed (cost per SSI). Results: The budget impact of the use of antibacterial sutures resulted in a 24% of cost savings related to the normal sutures. It represents savings of € 5.4M per year for an average Spanish hospital, and € 1,264M per year for the whole Spanish Health System. The results of the sensitivity analysis shows that even by changing the effectiveness of the suture and using the most unfavourable data found in the literature for the cost of an SSI, the use of the antibacterial suture still produces savings of 24% compared with the use of normal suture. cOnclusiOns: This budget impact analysis provides new evidence that reinforces the use of antibacterial sutures, because it may reduce the risk of SSI, the negative effects of its consequences and associated costs and significantly improving the quality of care for surgical patients in Spain.

The full benefits of adult pneumococcal vaccination: A systematic review

“…In general, the 32 (21.3%) studies that present an analysis of PCV13 alone tend to take a more economically focused approach than the other included studies. Twenty-seven (84.4%) of these PCV13-only studies account for healthcare cost savings [ 55 , 63 , 64 , 80 , 82 , 87 , 91 , 98 , 110 , 117 , 123 , 127 , 128 , 130 – 132 , 150 , 151 , 153 , 156 – 158 , 168 , 173 , 178 , 184 , 194 ], compared with 79 (52.7%) of all included studies. Similarly, seven of these studies (21.9%) account for outcome-related productivity gains [ 81 , 87 , 98 , 117 , 127 , 132 , 157 ], which represents double the share of all included studies (10.7%).…”